首页> 外文期刊>Diabetes >Activation of Nrf2 Is Required for Normal and ChREBP-Augmented Glucose-Stimulated p-Cell Proliferation
【24h】

Activation of Nrf2 Is Required for Normal and ChREBP-Augmented Glucose-Stimulated p-Cell Proliferation

机译:Nrf2的激活是正常和ChREBP增强葡萄糖刺激的p细胞增殖所必需的。

获取原文
获取原文并翻译 | 示例
       

摘要

Patients with both major forms of diabetes would benefit from therapies that increase p-cell mass. Glucose, a natural mitogen, drives adaptive expansion of p-cell mass by promoting p-cell proliferation. We previously demonstrated that a carbohydrate response element-binding protein (ChREBP) is required for glucose-stimulated p-cell proliferation and that overexpression of ChREBPa amplifies the proliferative effect of glucose. Here we found that ChREBPa reprogrammed anabolic metabolism to promote proliferation. ChREBPa increased mitochondrial biogenesis, oxygen consumption rates, and ATP production. Proliferation augmentation by ChREBPa required the presence of ChREBPp. ChREBPa increased the expression and activity of Nrf2, initiating antioxidant and mitochondrial biogenic programs. The induction of Nrf2 was required for ChREBPa-mediated mitochondrial biogenesis and for glucose-stimulated and ChREBPa-augmented p-cell proliferation. Overexpression of Nrf2 was sufficient to drive human p-cell proliferation in vitro; this confirms the importance of this pathway. Our results reveal a novel pathway necessary for p-cell proliferation that may be exploited for therapeutic p-cell regeneration.
机译:两种主要形式的糖尿病患者都将从增加p细胞质量的疗法中受益。葡萄糖是一种天然的促分裂原,它通过促进p细胞增殖来促进p细胞质量的适应性扩展。我们以前证明,葡萄糖刺激的p细胞增殖需要碳水化合物反应元件结合蛋白(ChREBP),而ChREBPa的过表达会放大葡萄糖的增殖作用。在这里,我们发现ChREBPa重新编程了合成代谢代谢以促进增殖。 ChREBPa增加了线粒体的生物发生,耗氧率和ATP的产生。 ChREBPa促进增殖需要ChREBPp的存在。 ChREBPa增加了Nrf2的表达和活性,启动了抗氧化剂和线粒体的生物程序。 Nrf2的诱导是ChREBPa介导的线粒体生物发生以及葡萄糖刺激和ChREBPa增强的p细胞增殖所必需的。 Nrf2的过表达足以在体外驱动人p细胞的增殖。这证实了这一途径的重要性。我们的结果揭示了p细胞增殖所必需的新型途径,可用于治疗性p细胞再生。

著录项

  • 来源
    《Diabetes》 |2018年第8期|1561-1575|共15页
  • 作者单位

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Departments of Oncological Sciences and Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY;

    Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

    Division of Endocrinology and Metabolism and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC;

    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY,Departments of Oncological Sciences and Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY;

    Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:03

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号